FY2025 Earnings Forecast for XENE Issued By Leerink Partnrs

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Investment analysts at Leerink Partnrs dropped their FY2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings of ($3.80) per share for the year, down from their prior forecast of ($2.85). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals’ FY2026 earnings at ($5.00) EPS, FY2027 earnings at ($3.15) EPS and FY2028 earnings at ($2.45) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period in the prior year, the business earned ($0.73) EPS.

XENE has been the topic of a number of other research reports. Raymond James reaffirmed an “outperform” rating and set a $50.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $56.00.

Xenon Pharmaceuticals Trading Down 1.2 %

Xenon Pharmaceuticals stock opened at $39.98 on Friday. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of -14.18 and a beta of 1.20. Xenon Pharmaceuticals has a 1-year low of $35.53 and a 1-year high of $50.99. The firm has a 50 day simple moving average of $40.28 and a 200 day simple moving average of $40.79.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Blue Trust Inc. raised its stake in Xenon Pharmaceuticals by 174.7% during the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 641 shares during the period. Avior Wealth Management LLC bought a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at approximately $101,000. nVerses Capital LLC purchased a new position in shares of Xenon Pharmaceuticals during the third quarter valued at approximately $102,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 487 shares in the last quarter. Finally, KBC Group NV grew its position in shares of Xenon Pharmaceuticals by 39.8% during the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 780 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Insider Transactions at Xenon Pharmaceuticals

In related news, Director Gary Patou sold 4,891 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the sale, the director now directly owns 23,573 shares in the company, valued at approximately $968,378.84. This trade represents a 17.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ian Mortimer sold 22,468 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $40.20, for a total value of $903,213.60. Following the transaction, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,258,340.40. The trade was a 41.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,383 shares of company stock valued at $2,535,891 in the last ninety days. 5.52% of the stock is currently owned by corporate insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.